Guanilated Quinolones with Dual Antitubercular and Anti‐Inflammatory Activities
ChemMedChem · 2026-05-27 · 21 (10)
DOI: 10.1002/cmdc.70319 ↗At a glance
Journal article in ChemMedChem, published online on 2026-05-27. Written by Mamorunyane Morale and 8 co-authors. Institution: Centre of Excellence for Pharmaceutical Sciences, North-West University, Potchefstroom, South Africa. Major MEDLINE topics: Antitubercular Agents, Quinolones, Mycobacterium tuberculosis, Anti-Inflammatory Agents. 32 references. Funded by: South African Medical Research Council, Seattle Tuberculosis Research Advancement Center (SEATRAC) at the University of Washington/Seattle Children's Research Institute/Fred Hutch Center for AIDS Res…, SAMRC.
Abstract (original language)
Host‐directed therapy (HDT) for tuberculosis (TB) generally involves the addition of adjuvant(s) to the standard TB regimen of at least four drugs with the hope of reducing treatment duration. Potential clinical challenges with the addition of adjuvant (s) to the TB regimen are increased pill load, which may lead to nonadherence, and consequently the precipitation of drug resistance; as well as the issue of drug–drug interactions. Molecules that can concurrently act as HDT and antitubercular agent thus have the potential to reduce TB treatment duration, and the pill burden, which may ultimately lead to a simplified TB regimen. To this end, we investigated novel guanilated quinolones as dual inhibitors of Janus Kinase 3 (host target) and Mycobacterium tuberculosis. Compound 13 was identified with potent Janus Kinase 3 inhibitory activity—exhibiting 98% enzyme inhibition at 1 µM, and antitubercular activity in the range of 0.2–6 µM in two different growth media.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Centre of Excellence for Pharmaceutical Sciences, North-West University, Potchefstroom, South Africa.
- Molecular Mycobacteriology Research Unit, Department of Pathology and Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory, South Africa.
- Wellcome Centre for Infectious Diseases Research in Africa (CIDRI-Africa), Institute of Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Observatory, South Africa.
- Center for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, Washington, USA.
- Department of Tropical Disease Biology, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, Merseyside, UK.
ORCID profiles: Audrey Jordaan, Digby F Warner, Richard M Beteck
Funding
- South African Medical Research Council
- Seattle Tuberculosis Research Advancement Center (SEATRAC) at the University of Washington/Seattle Children's Research Institute/Fred Hutch Center for AIDS Res…
- SAMRC
Cite
APA
Morale, M., Dube, P. S., Jordaan, A., Legoabe, L. J., Warner, D. F., Allen, R., Repasy, T., Parish, T., & Beteck, R. M. (2026). Guanilated Quinolones with Dual Antitubercular and Anti‐Inflammatory Activities. ChemMedChem, 21(10). https://doi.org/10.1002/cmdc.70319
Vancouver
Morale M, Dube PS, Jordaan A, Legoabe LJ, Warner DF, Allen R, et al. Guanilated Quinolones with Dual Antitubercular and Anti‐Inflammatory Activities. ChemMedChem. 2026;21(10). doi:10.1002/cmdc.70319
BibTeX
@article{Morale2026,
author = {Morale, Mamorunyane and Dube, Phelelisiwe S and Jordaan, Audrey and Legoabe, Lesetja J and Warner, Digby F and Allen, Renee and Repasy, Teresa and Parish, Tanya and Beteck, Richard M},
title = {Guanilated Quinolones with Dual Antitubercular and Anti‐Inflammatory Activities},
journal = {ChemMedChem},
year = {2026},
volume = {21},
number = {10},
doi = {10.1002/cmdc.70319}
}
EUVIMED